| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8536853 | Pharmacology & Therapeutics | 2018 | 59 Pages |
Abstract
There are over 50 bispecific antibodies currently on clinical trials for various malignancies and the hope is that in the future many of these, with better understanding of principles and techniques of production, will provide treatment options for many different types of cancer.
Keywords
FDACLLmCRCEpCAMBsAbNHLB-ALLDLTMRDMTDALTCRSBlinatumomabADCCBiTEsCatumaxomabEMAGGTTEAEASTAspartate aminotransferaseAlanine aminotransferaseALPAlkaline phosphataseHuman anti-mouse antibodyantibody-dependent cell-mediated cytotoxicitybispecific antibodyBispecific antibodiesEuropean Medicines agencyimmunoglobulin overall survivalstable diseaseprogressive diseaseMinimal residual diseaseMaximum tolerated doseIntravenousdose limiting toxicityFood and Drug AdministrationColorectal cancerNSCLCNon-small cell lung cancerMetastatic colorectal cancerNatural killer cellsCytokine Release SyndromeAdverse eventsnon-Hodgkin's lymphomaB-cell acute lymphoblastic leukemiaAcute lymphoblastic leukemiaChronic lymphoblastic leukemiaepithelial cell adhesion moleculeTRAbHAMAALLPartial responsecomplete responseCRCGamma-glutamyl transferase
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacology
Authors
Anuradha Krishnamurthy, Antonio Jimeno,